Finoriq research workspace
Indivior Pharmaceuticals, Inc. (INDV) SEC Filings & Filing Highlights
Indivior Pharmaceuticals, Inc. engages in the development, manufacture, and sale of. Review INDV SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- Company
- Indivior Pharmaceuticals, Inc. (INDV)
- Ticker
- INDV
- Market Cap
- $4.9B
- Latest Price
- $39.55
- Industry
- Biotech & Pharma
Indivior Pharmaceuticals, Inc. (INDV) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Indivior Pharmaceuticals, Inc. (INDV).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesThe Company held a virtual annual meeting of stockholders on May 13, 2026, at 10:00 a.m. Eastern Time. A total of 121,922,058 shares of com... | 8-K5.07 | 2026-05-15 |
| (b) Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant")...(b) Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scienti... | 8-K5.02 | 2026-05-15 |
| Indivior Announces $175 Million Accelerated Share RepurchaseIndivior Announces $175 Million Accelerated Share Repurchase | 8-K8.01 | 2026-05-04 |
| Indivior Announces $175 Million Accelerated Share RepurchaseIndivior Announces $175 Million Accelerated Share Repurchase | 8-K7.01 | 2026-05-04 |
| Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 GuidanceIndivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance | 8-K7.01 | 2026-04-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.